Telix Pharmaceuticals Limited (TLX) fair value analysis
Nasdaq · Updated 2026-10-19
TLX price how computed
Valuation status
No fair-value estimate yetTLX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for TLX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $10.69
- Sector
- Healthcare
- 12-month range
- $6.41–$12.83
- Market cap
- $3.63B
- From 52-week high
- -16.7%
- Shares outstanding
- 340M
- Rank in Healthcare by quality score
- #130 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Telix Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes diagnostic and therapeutic products based on radiopharmaceutical technology. The company operates globally with operations in multiple regions including Australia, Europe, and North America.
TLX currently ranks #130 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $3.63B
- P/E (trailing)
- 205x
- Revenue (TTM)
- $2.5B
- Net margin
- 3.3%
- EPS (TTM)
- $0.05
- Gross margin
- 51.6%
- Debt / equity
- 1.19
- Revenue growth (3-yr avg)
- 6357.5%
- Shares outstanding
- 340M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 35 · neutral
- 50-day average
- $11.52
- 200-day average
- $9.80
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Last 6 quarters vs consensus
- 3 beat, 2 missed
- Quarter by quarter
- 2025-12 ▼ miss (-48.1%)
2025-09 ▲ beat (+35.3%)
2025-06 ▼ miss (-95.3%)
2025-03 ▲ beat
2024-12 ▲ beat
2024-09 ▬ met
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $20.6
- Target vs last price
- +92.7%
What our data shows for TLX
- Shares are trading in the upper third of their 12-month price range of $6.41–$12.83.
- The 14-day relative strength index sits at a neutral 35.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TLX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the TLX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for TLX show a decline in quality grade this week, moving from C to D. This downgrade suggests a weakening in the company's fundamental quality metrics within the healthcare sector. The stock's valuation verdict remains under review pending completion of the full valuation analysis.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for TLX show a shift in the 50/200-day trend state from uptrend to mixed this week, reflecting a change in the stock's intermediate momentum characteristics. The valuation verdict remains at awaiting full valuation, indicating that a comprehensive assessment is still in development. This trend transition suggests movement away from the previously established upward momentum pattern.
- 2026-09-28 — TLX's 50/200-day trend state shifted from mixed to uptrend this week, indicating strengthening momentum in the near-term relative to the longer-term direction. The Healthcare sector company remains under valuation review, with a full verdict still pending. This trend improvement represents a notable shift in the technical positioning of the stock relative to its recent price history.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TLX stock undervalued?
TickrTrends has no fair-value estimate for TLX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is TLX's TickrTrends verdict?
TLX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does TLX compare to other Healthcare stocks?
TLX ranks #130 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TLX overbought or oversold?
TLX's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does TLX usually beat earnings estimates?
Over its last 6 reported quarters TLX beat the consensus estimate 3 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TLX?
Of 5 analysts covering TLX, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $20.6 (+92.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.